Oltipraz therapy in patients with liver fibrosis or cirrhosis: A randomized, double-blind, placebo-controlled phase II trial

Journal of Pharmacy and Pharmacology

Volumn 63, Issue 5, 2011, Pages 627-635

  Kim, Sang Geon ^a   Kim, Young Mi ^a   Choi, Jong Young ^b   Han, Joon Yeol ^b   Jang, Jeong Won ^b   Cho, Se Hyun ^b   Um, Soon Ho ^c   Chon, Chae Yoon ^d   Lee, Dong Hoo ^e   Jang, Ja June ^f   Yu, Eunsil ^g   Lee, Young Sok ^b  

^a Seoul National University   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c Korea University Ansan Hospital   (South Korea)

^d Yonsei University   (South Korea)

^e Hanyang University College of Medicine   (South Korea)

^f Seoul National University Hospital   (South Korea)

^g Asan Medical Center   (South Korea)

Author keywords

clinical trial; liver fibrosis and cirrhosis; oltipraz; TGF 1

Indexed keywords

COLLAGEN; OLTIPRAZ; PLACEBO; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; ARTICLE; BLOOD ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; ISHAK FIBROSIS SCORE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PILOT STUDY; POPULATION RESEARCH; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADULT; ANTICARCINOGENIC AGENTS; BIOLOGICAL MARKERS; BIOPSY; COLLAGEN; DOUBLE-BLIND METHOD; FEMALE; HEPATITIS B; HEPATITIS C; HUMANS; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PYRAZINES; TRANSFORMING GROWTH FACTOR BETA1;

EID: 79954780467     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2011.01259.x     Document Type: Article

References (33)

1. DeBakey SF, et al,. Liver cirrhosis mortality in the United States, 1970-1993. National Institute on Alcohol Abuse and Alcoholism; Surveillance Report #41, 1996.
2. Yoon Y, et al,. Liver cirrhosis mortality in the United States, 1970-1998. National Institute on Alcohol Abuse and Alcoholism; Surveillance Report #57, 2001.
3. Kakizoe T,. Cancer Statistics in Japan 1999. Tokyo: Foundation for Promotion of Cancer Research, 1999.
4. Yao FY, et al,. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. Hepatology 2001; 34: 411-416. (Pubitemid 32702355)
5. Dienstag JL, et al,. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003; 124: 105-117. (Pubitemid 36055344)
6. Freidman SL,. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. N Engl J Med 1993; 328: 1828-1835.
7. Gressner AM, Weiskirchen R,. Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets. J Cell Mol Med 2006; 10: 76-99. (Pubitemid 44874293)
8. Qi Z, et al,. Blockade of type beta transforming growth factor signaling prevents liver fibrosis and dysfunction in the rat. Proc Natl Acad Sci USA 1999; 296: 2345-2349. (Pubitemid 29117917)
9. Petrides AS, et al,. Pathogenesis of glucose intolerance and diabetes mellitus in cirrhosis. Hepatology 1994; 19: 616-627. (Pubitemid 24066891)
10. Cavallo-Perin P, et al,. Mechanism of insulin resistance in human liver cirrhosis. Evidence of a combined receptor and postreceptor defect. J Clin Invest 1985; 75: 1659-1665. (Pubitemid 15039491)
11. Dixon JB, et al,. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001; 121: 91-100. (Pubitemid 32591518)
12. Wattenberg LW, Bueding E,. Inhibitory effects of 5-(2-pyrazinyl)-4- methyl-1,2-dithiol-3-thione (oltipraz) on carcinogenesis induced by benzo[a]pyrene, diethylnitrosamine and uracil mustard. Carcinogenesis 1986; 7: 1379-1381.
13. Bolton MG, et al,. Transient intervention with oltipraz protects against aflatoxin-induced hepatic tumorigenesis. Cancer Res 1993; 53: 3499-3504. (Pubitemid 23229626)
14. Clapper ML, et al,. Chemopreventive activity of oltipraz against N-nitrosobis(2-oxopropyl)amine-induced ductal pancreatic carcinoma development and effects on survival of Syrian golden hamsters. Carcinogenesis 1995; 16: 2159-2165.
15. O'Dwyer PJ, et al,. Modulation of gene expression in subjects at risk for colorectal cancer by the chemopreventive dithiolethione oltipraz. J Clin Invest 1996; 98: 1210-1217. (Pubitemid 26299934)
16. Benson AB 3rd, et al,. Chronic daily low dose of 4-methyl-5-(2-pyrazinyl) -1,2-dithoiole-3-thione (Oltipraz) in patients with previously resected colon polyps and first-degree female relatives of breast cancer patients. Clin Cancer Res 2000; 6: 3870-3877.
17. Wang JS, et al,. Protective alterations in phase 1 and 2 metabolism of aflatoxin B1 by oltipraz in residents of Qidong, People's Republic of China. J Natl Cancer Inst 1999; 91: 347-354.
18. Jacobson LP, et al,. Oltipraz chemoprevention trial in Qidong, People's Republic of China: study design and clinical outcomes. Cancer Epidemiol Biomarkers Prev 1997; 6: 257-265. (Pubitemid 27172891)
19. Kang KW, et al,. Oltipraz regenerates cirrhotic liver through CCAAT/enhancer binding protein-mediated stellate cell inactivation. FASEB J 2002; 16: 1988-1990.
20. Kang KW, et al,. Inhibition of dimethylnitrosamine-induced liver fibrosis by [5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione] (oltipraz) in rats: suppression of transforming growth factor-beta1 and tumor necrosis factor-alpha expression. Chem Biol Interact 2002; 139: 61-77. (Pubitemid 34135997)
21. Bae EJ, et al,. Identification of a novel class of dithiolethiones that prevent hepatic insulin resistance via the adenosine monophosphate-activated protein kinase-p70 ribosomal S6 kinase-1 pathway. Hepatology 2007; 46: 730-739.
22. Hwahng SH, et al,. Role of adenosine monophosphate-activated protein kinase-p70 ribosomal S6 kinase-1 pathway in repression of liver X receptor-alpha-dependent lipogenic gene induction and hepatic steatosis by a novel class of dithiolethiones. Hepatology 2009; 49: 1913-1925.
23. Ishak K, et al,. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-699.
24. Medical review part I and statistical review part I of the drug approval package for adefovir dipivoxil (NDA 21-449). 2002. Available at
25. Suzuki Y, et al,. Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection. J Hepatol 1999; 30: 743-748. (Pubitemid 29248970)
26. Kim SG, et al,. Pharmacokinetics of oltipraz and its major metabolite (RM) in patients with liver fibrosis or cirrhosis: relationship with suppression of circulating TGF-β1. Clin Pharmacol Ther 2010; 88: 360-368.
27. Ginès P, et al,. Management of cirrhosis and ascites. N Engl J Med 2004; 350: 1646-1654.
28. Crowell JA, et al,. Chronic toxicity studies of 5-(2-pyrazinyl)-4-methyl- 1,2-dithiole-3-thione, a potential chemopreventive agent. Fundam Appl Toxicol 1997; 35: 9-21.
29. el Tayeb M, et al,. Praziquantel and oltipraz: the treatment of school children infected with Schistosoma mansoni and/or Schistosoma haematobium in Gezira, Sudan. Ann Trop Med Parasitol 1988; 82: 53-57.
30. Dimitrov NV, et al,. Oltipraz concentrations in plasma, buccal mucisa cells, and lipids: pharmacological studies. Cancer Epidemiol Biomarkers Prev 2001; 10: 201-207. (Pubitemid 34288530)
31. Benson AB 3rd, et al,. Phase I study of 5-(2-pyrazinyl)-4-methyl-1,2- dithoiole-3-thione (Oltipraz, RP35972) in male patients with previously resected colon polyps and first degree relatives of breast cancer patients. Proc Am Soc Clin Oncol 1992; 11: 145.
32. Flisiak R, et al,. Circulating transforming growth factor beta1 as an indicator of hepatic function impairment in liver cirrhosis. Cytokine 2000; 12: 677-681. (Pubitemid 30453497)
33. Neuman MG, et al,. Serum tumour necrosis factor-alpha and transforming growth factor-beta levels in chronic hepatitis C patients are immunomodulated by therapy. Cytokine 2002; 17: 108-117.